Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$4.76
+$0.14 · +3.03%
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Previous close
$4.76
+$0.14 · +3.03%
After-hours
$4.77
+$0.01 · +0.21%
Oct 8, 7:50 PM ET
Regular session · ET · Market data may be delayed.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Day range
Current $4.76
52-week range
Current $4.76
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
38
Bearish
Risk
69
High Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Day range
Current $4.76
52-week range
Current $4.76
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44.55M USD | 57.56M USD | 50.58M USD | 47.68M USD | 50.83M USD |
| Cost of goods sold | 17.15M USD | 17.87M USD | 20.83M USD | 19.39M USD | 14.99M USD |
| Gross profit | 27.39M USD | 39.69M USD | 29.75M USD | 28.29M USD | 35.84M USD |
| Research and development | 17.19M USD | 20.28M USD | 13.1M USD | 17.48M USD | 17.05M USD |
| Selling, general, and administrative | 79.85M USD | 50.18M USD | 31.75M USD | 52.88M USD | 53.48M USD |
| Operating expenses | 97.04M USD | 70.46M USD | 44.85M USD | 70.36M USD | 70.52M USD |
| Interest income | — | 3.44M USD | 16.32M USD | 99K USD | 423K USD |
| Interest expense | 17.1M USD | 16.82M USD | 7.46M USD | 12.44M USD | 22.46M USD |
| Depreciation and amortization | 548K USD | 718K USD | 1.35M USD | 2.39M USD | 2.96M USD |
| Operating income | −69.65M USD | −30.77M USD | −15.1M USD | −42.07M USD | −34.68M USD |
| Net income | −83.78M USD | −44.14M USD | −7.87M USD | −54.41M USD | −70.54M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$11.00
131.09% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI17.39M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM13.27M0.02%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF5.58M0.01%95.4B USD0.05%$233.13-0.15%
State Street SPDR S&P Pharmaceuticals ETFXPH5.53M1.20%453.39M USD0.35%$63.63+1.14%
Vanguard Russell 2000 ETFVTWO3.17M0.02%18B USD0.06%$112.1-0.10%
iShares Russell 2000 Growth ETFIWO1.74M0.01%14.04B USD0.24%$353.47-0.53%
iShares Micro-Cap ETFIWC1.58M0.12%1.32B USD0.60%$182.79-0.31%
Simplify Propel Opportunities ETFSURI1.33M1.77%74.84M USD2.82%$17.07+1.31%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
